MORF

Morphic Holding, Inc.

39.48 USD
+2.53 (+6.85%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Morphic Holding, Inc. stock is up 24.58% since 30 days ago. The next earnings date is Apr 23, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 March’s closed higher than February. In the last 3 Unusual Options Trades, there were 3 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
01 Feb 19:04 16 Feb, 2024 35.00 CALL 387 3
01 Feb 19:04 19 Apr, 2024 35.00 CALL 91 25
01 Feb 19:04 15 Mar, 2024 35.00 CALL 250 0

About Morphic Holding, Inc.

Morphic Holding, Inc. discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the. treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis. and fibrosis diseases. The company is also developing avß6 and avß8 to treat solid tumors.